Publication for CD33 and CLEC12A

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CD33	CD33 molecule	945			[link]
hsa	CLEC12A	C-type lectin domain family 12 member A	160364

Pubmed ID	Priority	Text
31695916	0.97	CD33, CD123 and CLL-1 (SGN-CD33A, IMGN779, IMGN632, CLT030) are under active development.
	0.90	CD33 and CD123, CLL-1 is completely absent on normal HSCs, making it an ideal therapeutic target for AML.
29316944	0.96	CLL-1+, CD33+, and CD34+ cells in primary AML samples (n = 37-40, from a diverse range of AML subtypes; see Additional file 1: Table S1); NS not significant.
	0.93	CD33 and CD34 are classic markers for AML, we measured the expression of these two markers in combination with CLL-1 on primary AML samples.
	0.89	CLL-1, while most of the granulocyte and monocyte precursor cells (CD34+CD33+) expressed CLL-1 at high levels, in contrast CD34+CD33- cells showed virtually no expression of CLL-1.
29946192	0.95	CD33 (98.1%), CD123 (98.1%), CLL1 (71.4%), TIM3 (80.0%) and CD244 (97.1%).
	0.94	CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML.
	0.94	CD33, CD123, CLL1, TIM3 and CD7.
	0.91	CD33, CLL1, TIM3 and CD244 to be significantly less expressed on LSC, both at initial diagnosis and at relapse.
	0.90	CD33/TIM3 and CLL1/TIM3 revealed non-overlapping expression patterns in normal tissues: Excluding organs with known immune infiltration, dual expression of CD33/TIM3 was only found in bladder.
	0.88	CD33/TIM3 and CLL1/TIM3 to be highly positive in AML compared with normal hematopoiesis and non-hematopoietic tissues.
	0.83	CD33 (96.4%), CD123 (97.0%), CLL1 (80.1%), TIM3 (87.3%) and CD244 (96.7%).
	0.66	CD33, CD123, CLL1, TIM3 or CD244 may have antileukemic efficacy in most AML patients.
	0.64	CD33, CD123, CLL1, TIM3 and CD244 in most cases at initial diagnosis and relapse, irrespective of the genetic background.
	0.55	CD33, CD123, CLL1, CD47, CD96, CD157, CD244, TIM3 and CD7, have been reported to be expressed on leukemic stem cells (LSC).
25056598	0.95	CLL-1 targeting BiFab, alphaCLL1-alphaCD3, and a comparison of its in vitro and in vivo activity to a similarly constructed CD33 targeting BiFab, alphaCD33-alphaCD3.
	0.93	CD33 and CLL1 expression levels (U937: CD33 and CLL1 high; KASUMI-3: CD33 and CLL1 medium; and KG-1A: CD33 and CLL1 low; see Fig. S3) were used to compare the cytotoxicities of BiFabs after a 24h incubation period.
	0.90	CD33 and CLL1 expression in patients reveals simultaneous expression in most patients, but cases of single antigen expression (CD33+/CLL1- or CD33-/CLL1+) have also been reported in the literature and were observed in our AML patient samples.
	0.86	CD33- and CLL1- human B-lymphoblast cell line, RS4;11 (Fig. S2).
29716633	0.95	CD33, CD123, CD38, CD44v6, FRbeta, PR1/HLA-A2, CLL-1, and LeY. CD33 and CD123 are highly expressed on primary AML cells and are the most commonly used antigens for AML treatment by CAR-T therapy.
31623224	0.95	CLEC12A), which is highly expressed also on CD33- AML cells and could better contribute to myeloid leukemia targeting by NK cells.
32185132	0.95	CD33, C-type lectin-like molecule 1 (CLL-1), and Lewis-Y. Additional targets under preclinical investigation include CD135 (FLT-3 receptor), Folate receptor beta, CD44v6, WT1, B7-H3, CD70, and CD7.
31014360	0.93	CLL1/CD33/CD38/CD56/CD123 from China is enrolling patients with refractory or relapsed AML; it plans to enroll 10 patients between 2 and 75 years old and aims to evaluate the feasibility, safety, and efficacy of the fourth generation CAR-T cells, estimated completion date is December 31, 2020.
	0.87	CLL-1 or CD33-positive on both AML cell lines and primary AML cells.
	0.76	CLL-1 are mainly on anti-CLL-1 antibodies, the first successful utilization in human has inspired more interests in targeting CLL-1 for AML, it can be expected an increasing number of researches on CLL-1 CAR-T will emerge, especially the combination with other markers such as CD123 or CD33 or with novel agents such as FLT3 or BCL-2 inhibitor.
	0.59	CLL-1-CD33 CAR-T cells was firstly used after T cell-depleting conditioning therapy with fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 for 3 consecutive days.
27872732	0.93	CD33, CD44) and a marker cocktail (CLL-1/TIM-3/CD7/CD11b/CD22/CD56) in one fluorescence channel.
30953030	0.92	CD33 and CLL-1 (CD371) compared to CD34+/CD38- MCL cells (Figure 2, Table 2).
31547472	0.90	CD33, CLL1, TIM3, CD244, CD47, CD96, CD157 and CD7 were ubiquitously expressed on AML bulk cells at diagnosis and relapse, irrespective of genetic features.
31470642	0.87	CD33, CD44, CD123, CD135 (FLT3), CD371 (CLL-1), and Lewis Y (LeY).
	0.79	CD33, CD123, and CLEC12A/CLL-1 (CD371).
30524966	0.84	CD33, CD45, CD123, FLT3, Lewis-Y, and CLL-1 [reviewed in ].
29799854	0.82	C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A), CD13/CD33, CD44 and CD47 in a differentiation-stage specific manner.
31221785	0.81	CLL-1, which was targeted in the above-mentioned combinatorial approach in combination with CD33 by Liu et al. also has potential utility as a standalone antigen, with pre-clinical data suggesting that differential expression between malignant and healthy blasts may be sufficient to preserve hematopoeisis.
	0.52	CD33-CLL1 CART (CLL1=C-type lectin molecule-1) were reported at the American Society of Hematology (ASH) annual meeting in 2018, though no data have been presented to date for the rest of this cohort (clinicaltrials.gov identifier: 03795779).
29017060	0.78	CLL1, CD33, CD44, CD96, CD47, CD32 and CD25, TIM3, CD99, adding another 80 proteins (Figure 1 - orange boxes and Figure S1B).
	0.66	CD33+ADGRE2, CLEC12A+CCR1, CD33+CD70 and LILRB2+CLEC12A, in greater depth, examining their expression in primary AML specimens.